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Abstract
Aberrant double-stranded break (DSB) repair leads to genomic instability, which is a hallmark of malignant cells.
Double-stranded breaks are repaired by two pathways: homologous recombination (HR) and nonhomologous DNA
end joining (NHEJ). It is not known whether these repair pathways are affected in sporadic breast tumors. Here, we
examined the efficiency of HR and NHEJ repair in a panel of sporadic breast cancer cell lines and tested whether
the efficiency of HR or NHEJ correlates with radioresistance. Homologous recombination and NHEJ in breast cancer
cells were analyzed using in vivo fluorescent assays. Unexpectedly, our analysis revealed that the efficiency of HR is
significantly elevated in breast cancer cells compared with normal mammary epithelial cells. In contrast, the efficiency
of NHEJ in breast cancer cells is not different from normal cells. Overall, breast cancer cells were more sensitive
to radiation than normal cells, but the levels of resistance did not correlate with either HR or NHEJ efficiency. Thus,
we demonstrate that sporadic breast cancers are not associated with a deficiency in DSB repair, but rather with up-
regulation of the HR pathway. Our finding of elevated HR in sporadic breast cancer cell lines suggests that therapies
directed against the components of HR will be highly tumor-specific.
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Introduction
Genomic rearrangements such as translocations, deletions, and duplica-
tions are extremely frequent in cancer cells and, particularly, in breast
cancer cells [1–4]. Genomic rearrangements are believed to result from
the aberrant repair of DNA double-strand breaks (DSBs). These DSBs
are repaired by two major pathways: homologous recombination
(HR) and nonhomologous end joining (NHEJ; reviewed in Helleday
et al. [5]). Homologous recombination is conducted by proteins from
the Rad52 epistasis group and is dependent on BRCA1 and BRCA2
breast cancer susceptibility genes (reviewed in San Filippo et al. [6])
and possibly on the members of the Fanconi Anemia pathway [7].
During HR-mediated repair of DSB, the sister chromatid is used as a
template to copy the missing information into the broken locus. Be-
cause sister chromatids are identical to each other, DNA damage can
be repaired faithfully with no genetic consequence. Nonhomologous
DNA end joining is mediated by Ku70/Ku80, DNA-PKcs, Artemis
nuclease, and the XRCC4/DNS-LigaseIV complex (reviewed in Lieber
[8]). The NHEJ pathway fuses the two broken DNA ends with little or
no sequence homology, leading to deletions or insertions of filler DNA.
Defects in HR or NHEJ factors may lead to radiosensitivity and a
predisposition to cancer, as is the case with BRCA1 and BRCA2, which
are mutated in familial breast cancer [9]. It should be noted that BRCA
proteins function in transcription, cell cycle control, and ubiquitination
[10]. However, BRCA mutations account for only a small percentage
of cancer cases and the status of DSB repair is less clear in sporadic
breast cancers, which are not associated with an obvious DNA repair
defect. On the contrary, it was suggested that an increase in DNA re-
pair capacity may contribute to therapy resistance [11,12]. Thus, there
are conflicting hypotheses as to whether DSB repair is upregulated
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or downregulated in breast cancer. Overexpression of Rad51, a key
enzyme in the HR pathway, has been detected in various cancer cells
[13–23]. We previously showed that the Rad51 promoter is strongly
upregulated in several sporadic breast cancer cell lines and that Rad51
promoter fused to the diphtheria toxin open reading frame (ORF) selec-
tively targets cancer cells [23].
Here, we performed a systematic analysis of HR and NHEJ effi-
ciency and radiosensitivity in a panel of sporadic breast cancer cell
lines and in normal breast epithelial cells. Homologous recombination
and NHEJ were measured using in vivo fluorescent assays in which
cells were transfected with green fluorescent protein (GFP)–based re-
porter substrates from which functional GFP would only be expressed
if successful DSB repair occurred. Our analysis revealed that HR effi-
ciency is significantly increased in breast cancer cells, whereas NHEJ
efficiency does not differ from that in normal breast cells. Survival after
γ-irradiation did not correlate with either HR or NHEJ efficiency. Our
results provide insight into the etiology of breast cancer: cancer cells
upregulate HR, possibly to mitigate the replication-associated damage,
and also under pressure to rearrange their genomes and evade host
surveillance systems, but this increased HR does not lead to radio-
resistance. Another important implication of our study is that the
HR pathway is a promising target for anticancer therapy.
Materials and Methods
Breast Cell Lines and Culture Conditions
The following breast cells were used: 1) normal human mammary
epithelial cells HMEC1,HMEC2,HMEC3, andHMEC4; 2) cell lines
derived from primary tumors HCC1954, HCC202, HCC70, and
HCC2218; and 3) cell lines derived from metastatic tumors MCF-7,
T47-D, MDA-MB-231, and MDA-MB-468. Human mammary epi-
thelial cells were derived from four female donors: HMEC1, HMEC3,
andHMEC4donors werewhite, andHMEC2donor was black.Human
mammary epithelial cells were obtained from Clonetics, Walkersville,
MD. All other cell lines were obtained from American Type Culture
Collection (Manassas, VA). Cells were cultured in 5% CO2 and 3%
O2 at 37°C. Human mammary epithelial cells were cultured in mam-
mary epithelial growth medium (MEGM) BulletKit (CC-3150;
Clonetics) supplemented with 100 units/ml penicillin and 100 μg/ml
streptomycin. Breast cancer cell lines were cultured according to ATCC
recommendations. HCC1954, HCC70, HCC202, and HCC2218
cells were cultured in RPMI 1640 medium (ATCC 30-2001) sup-
plemented with 10% fetal bovine serum, 100 units/ml penicillin, and
100 μg/ml streptomycin. MCF-7 cells were grown in Eagle’s minimal
essential medium (ATCC 30-2003) supplemented with 0.01 mg/ml
bovine insulin, 10% fetal bovine serum, 100 units/ml penicillin, and
100 μg/ml streptomycin. T47-D cells were cultured in RPMI 1640me-
dium supplemented with 0.2 mg/ml bovine insulin, 10% fetal bovine
serum, 100 units/ml penicillin, and 100 μg/ml streptomycin. Both
MDA-MB-231 andMDA-MB-468 cell lines were grown in Leibovitz’s
L-15 medium (ATCC 30-2008) supplemented with 10% fetal bovine
serum, 100 units/ml penicillin, and 100 μg/ml streptomycin.
Transfections
Plasmids containing NHEJ or HR reporter cassettes were linearized
by I-SceI or HindIII restriction enzymes and purified using Qiagen
Qiaex II purification kit (20021; Qiagen, Valencia, CA). Two days after
splitting, exponentially growing cells were transfected with 0.5 μg of the
NHEJ reporter construct, or 2 μg of the HR reporter constructs, and
0.1 μg of pDsRed-N1 as the internal control. The lower amount of the
pDsRed-N1 was used to avoid interference from the bright DsRed
fluorescence. Transfections were performed using the Amaxa Nucleo-
fector (Walkersville, MD). Human mammary epithelial cells were
transfected with HMEC Nucleofector kit (Amaxa VPA-1002) using
program Y-001 (a transfection program is a proprietary set of electrical
pulses preset by the manufacturer of the Nucleofector machine). All the
other cell lines were transfected with Cell Line Nucleofector kit V
(Amaxa VPA-1003). Cell lines HCC1954, HCC70, HCC202, and
MCF-7 were transfected using P-020 program. Cell lines HCC2218,
T47-D, MDA-MB-231, and MDA-MB-468 were transfected using
programs T-030, X-005, X-003, and X-005, respectively. In the process
of optimizing the transfection conditions, we used multiple Amaxa
transfection protocols for each of the cell lines. Variations in transfec-
tion protocol changed the transfection efficiency, but the DNA repair
efficiency expressed as GFP+/DsRed+ ratio was independent of the
transfection conditions.
FACS Analysis
Cells were analyzed on the FACScalibur machine (BD Biosciences,
San Jose, CA) using a green-versus-red fluorescent plot as described in
Seluanov et al. [24]. Data were analyzed with the Cell Quest software
(BD Biosciences).
Gamma Irradiation and Clonogenic Survival Assays
Cells were split 2 days before γ-irradiation. Cells were irradiated
with increasing doses of γ-irradiation ranging from 0 to 6 Gy using
a Gammacell 1000 irradiator (625 Ci 137Cs from Atomic Energy of
Canada, Ltd., Gaithersburg, MD). Serial dilutions of irradiated cells
were plated immediately after irradiation (within 15 minutes). Cells
were incubated for 7 to 10 days and stained with Commassie reagent
(0.25% Commassie, 50% methanol, and 10% acetic acid) for 3 hours,
after which the Commassie reagent was washed out with distilled water.
Colonies containing at least 50 cells were counted. Survival was ex-
pressed as the relative plating efficiencies of the irradiated to control cells.
Statistical Analysis
The doses of γ-irradiation that kill 50% (LD50) and 75% (LD75) of
the test population of experimental cells were estimated using a two-
parameter logistic model to model the relationship between dose of
γ-irradiation and the probability of cell survival. This was done sepa-
rately for each of the 12 cell lines using data from three to four replicas
of the dose-response experiment. Analyses were done using SAS version
9.0 (SAS Institute, Inc., Cary, NC).
Results
Homologous Recombination Is Increased in Breast
Cancer Cells While NHEJ Is Not
Genomic instability, such as translocations and deletions, are a
hallmark of cancer cells, including breast cancer cells [1–4]. Genomic
rearrangements can arise as a result of the abnormal repair of DNA
double-strand breaks by HR or NHEJ. To study whether HR and
NHEJ are altered in breast cancer cells, we examined a panel of breast
cell lines. As a normal control, we used primary human mammary epi-
thelial cells HMEC1, HMEC2, HMEC3, and HMEC4. To examine
breast cancer cells representing different stages of the disease, we
chose four cell lines derived from primary breast tumors HCC1954,
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HCC202, HCC70, and HCC2218 and four cell lines from metastatic
tumors MCF-7, T47-D, MDA-MB-231, and MDA-MB-468.
To analyze the efficiency of NHEJ and HR in a quantitative manner,
we used fluorescent reporter constructs in which a functional GFP gene
is reconstituted following an HR or NHEJ event (Figure 1) [24,25].
The NHEJ reporter (Figure 1A) consists of a GFP gene interrupted
by an engineered intron (GFP-Pem1) and an adenoviral exon flanked
by two HindIII and two inverted I-SceI sites. The starting construct
is GFP-negative because the adenoviral exon disrupts the GFP ORF.
Digestion with HindIII removes the adenoviral exon and leaves com-
patible DNA ends. Nonhomologous DNA end joining of the compat-
ible DNA ends (NHEJ-C) restores the functional GFP gene. Digestion
of inverted I-SceI sites leaves incompatible DNA ends. Similarly, NHEJ
of incompatible ends (NHEJ-I) restores GFP activity. Because radiation
and chemotherapy drugs cause unspecific damage to DNA, NHEJ-I
may bemore representative of theNHEJ of radiation-induced or chemi-
cally induced DNA damage. The functionality of the NHEJ cassette
has been confirmed by plasmid rescue and sequencing [24]. The HR
Figure 1. Reporter constructs for analysis of DSB repair. (A) Reporter plasmid for analysis of NHEJ. The reporter cassette consists of a GFP
gene under a CMV promoter with an engineered intron from the rat Pem1 gene, interrupted by an adenoviral exon (Ad). The adenoviral exon
is flanked by I-SceI recognition sites in inverted orientation for induction of DSBs. In this construct, the GFP gene is inactive; however, upon
induction of a DSB and successful NHEJ, the construct becomes GFP+. SA indicates splice acceptor; SA, splice donor; shaded squares,
polyadenylation sites. (B) Reporter plasmid for analysis of HR. The reporter cassette consists of two mutated copies of GFP-Pem1. In the
first copy of GFP-Pem1, the first GFP exon contains a deletion of 22 nt and an insertion of two I-SceI recognition sites in inverted orientation.
The 22 nt deletion ensures that GFP cannot be reconstituted by a NHEJ event. The second copy of GFP-Pem1 lacks the ATG and the second
exon of GFP. Upon induction of DSBs by I-SceI, gene conversion events reconstitute an activeGFP gene. (C) Repair products of the reporter
plasmid for the analysis of HR shown in (B). GC indicates gene conversion; SSA, single-strand annealing. Only gene conversion leads to
reconstitution of the GFP activity.
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Figure 2. Analysis of HR and NHEJ in normal and malignant breast epithelial cells. Cells were cotransfected with 2 μg (HR) or 0.5 μg
(NHEJ) linearized reporter plasmids (Figure 1) and 0.1 μg of the DsRed expression vector to normalize for the differences in transfection
efficiency. Cells were analyzed on a green-versus-red fluorescence plot. The gating for the analysis of GFP+ and DsRed+ cells was set
up using cells transfected with GFP or DsRed expression vectors and cells transfected with a negative control plasmid to exclude auto-
fluorescent cells. The numbers of GFP+ and DsRed+ cells were determined by flow cytometry, and typical FACS traces are shown on
the right. The ratio of GFP+ to DsRed+ cells was used as a measure of repair efficiency. (A) Efficiency of HR. (B) Efficiency of NHEJ of
compatible DNA ends generated by digestion of the NHEJ reporter plasmid with HindIII. (C) Efficiency of NHEJ of incompatible DNA
ends generated by digestion of the NHEJ reporter plasmid with I-SceI. All experiments were repeated at least four times. Error bars, SD.
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reporter (Figure 1B) consists of two defective copies of GFP-Pem1,
where the first copy contains two inverted recognition sites for I-SceI.
Digestion with I-SceI followed byHR repair by gene conversion restores
GFP activity (Figure 1C). The functionality of the HR reporter cassette
has been confirmed by isolating the GFP+ cells by flow cytometry, plas-
mid rescue, and sequencing. In the recovered HR cassettes, GFP gene
was reconstituted by a gene conversion event between the upstream
internally deleted copy of the first GFP exon and the downstream pro-
moterless copy of the first GFP exon.
To analyze HR, NHEJ-C, and NHEJ-I, we transfected cells with
the HR reporter linearized by digestion with I-SceI enzyme, or the
NHEJ reporter linearized byHindIII or I-SceI. The DSB reporter plas-
mids were cotransfected with a plasmid expressing DsRed to normal-
ize for differences in transfection efficiency between the cell lines.
After transfection cells were incubated for 72 hours to allow for the
maximum expression of GFP and DsRed and were analyzed by flow
cytometry. Cells were analyzed with a green-versus-red fluorescence
plot as described by Seluanov et al. [24]. The gating for GFP+ and
DsRed+ cells was determined in each experiment by using cells trans-
fectedwithGFP,DsRed, or negative control plasmids. The ratio between
GFP+ and DsRed+ cells was used as a measure of HR or NHEJ effi-
ciency (Figure 2).
The HR efficiency detected in normal breast epithelial cells was
low compared with the generally higher levels seen in breast cancer
cells, with HCC1954 and T47-D cell lines showing extremely high
HR (Figure 2A). We statistically evaluated whether the level of HR
differs between normal and malignant cells (Figure 3A). The analysis
showed that HR is significantly elevated in breast cancer cells (Mann-
Whitney test, PMWU = 0.017).
Human mammary epithelial cells are cultured in a proprietary
medium, which differs from the medium used for cancer cell lines. To
test whether theHMECmediummay have inhibitory effect onHR, we
attempted growing the HCC70, HCC1954, MDA-MB-468, T47-D,
MCF-7, and MDA-MB-231 cell lines in HMEC media. MDA-MB-
468, T47-D, MCF-7, and MDA-MB-231 cell lines died in HMEC
media; however, HCC70 and HCC1954 cells proliferated, enabling
us to analyze HR. Under these conditions, the efficiency of HR in the
cancer cells remained significantly higher than in the normal mammary
epithelial cells (Figure W1). This result indicated that the observed
differences in HR between the normal and malignant cells do not result
from the differences in the growth media.
The efficiency of both NHEJ-I and NHEJ-C was much higher than
the efficiency of HR, indicating that NHEJ is the preferred DSB repair
pathway in both normal and cancer cells (Figure 2, B and C). There
was, however, no correlation between the level of NHEJ and the nor-
mal versus malignant status (PMWU > 0.999 for NHEJ-I; PMWU =
0.734 for NHEJ-C; Figure 3B).
The two types of NHEJ showed strong correlation (rs = 0.979, P =
.001) indicating that the same machinery is involved in repair of com-
patible and incompatible DNA ends (Figure 3C ). In addition, there
was no significant correlation either between HR and NHEJ-I (rs =
0.329, P = .276) or between HR and NHEJ-C (rs = 0.273, P =
.366; Figure 3D). Thus, the two pathways of DSB repair are indepen-
dently controlled, and only HR is upregulated in breast cancer cells.
In summary, our analysis has revealed several important characteris-
tics of DSB repair in breast cancer cells: 1) HR is significantly elevated
in breast cancer cells compared with normal cells; 2) NHEJ is the
major DSB repair pathway in both normal and malignant breast epi-
thelial cells; 3) NHEJ efficiency does not differ significantly between
normal and cancerous cells; 4) there is a strong correlation between the
efficiency of NHEJ of compatible and incompatible DNA ends; and
5) there is no correlation between the efficiencies of HR and NHEJ.
Figure 3. Homologous recombination but not NHEJ is elevated in breast cancer cells. (A) Relationship between HR efficiency and normal
versusmalignant cell status. Cancer cells display elevated HR (PMWU = 0.017). (B) Relationship between NHEJ and normal versusmalig-
nant status. Nonhomologous DNA end joining efficiency does not differ between normal and cancer cells (PMWU > 0.999 for NHEJ-I;
PMWU= 0.734 for NHEJ-C). (C) There is a strong correlation between NHEJ of compatible and NHEJ of incompatible ends (rs = 0.979, P=
.001). (D) We did not detect a significant correlation either between HR and NHEJ-I (rs = 0.329, P= .276) or between HR and NHEJ-C (rs =
0.273, P = .366).
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HR and NHEJ Efficiencies Do Not Correlate
with Radiosensitivity
Increased efficiency of DSB repair may improve the ability of cells
to deal with DNA damage induced by irradiation. Because radio-
resistance is a serious problem in breast cancer treatment, we set out
to test whether an increase in HR or NHEJ contributes to this phe-
nomenon. We determined LD50 and LD75 after γ-irradiation for nor-
mal and cancer cell lines (Figure 4 and Table 1). Normal cells were
more resistant to γ-irradiation than cancer cells (LD50, PMWU = 0.014;
LD75, PMWU = 0.008; Figure 5A). Neither NHEJ-I nor NHEJ-C effi-
ciency correlated with radioresistance (NHEJ-I vs LD50, rs = −0.082,
P = .796; NHEJ-I vs LD75, rs = −0.027, P = .931; NHEJ-C vs LD50,
rs = −0.009, P = .977; NHEJ-C vs LD75, rs = 0.073, P = .818; Figure 5,
B and C).
Homologous recombination efficiency showed a significant negative
correlation with radioresistance (LD50, rs = −0.836, P = .008, LD75, rs =
−0.727, P = .022; Figure 5D). This seemingly contradicts the common
assumption that HR protects cells from radiation-induced death.
However, this correlation may be explained by the contribution of
normal cells, which have uniformly low HR efficiency and are also
more resistant to radiation. Indeed, when normal cells are omitted
from the analysis, the negative correlation betweenHR and survival dis-
appears (LD50, rs = −0.429, P = .294; LD75, rs = −0.107, P = .787).
Thus, when cancer cells are analyzed separately from normal cells, there
is no significant correlation between HR and survival, indicating that
increased HR in breast cancer cells does not lead to radioresistance.
Discussion
Our report shows that HR but not NHEJ is increased in breast
cancer cells compared with normal breast epithelial cells. This result
may have important implications for the development of anticancer
therapies targeting the HR pathway. Breast cancer is frequently asso-
ciated with chromosomal abnormalities [1–4], which could result
from the abnormal function of either the HR or NHEJ pathways,
with abnormal DSB repair meaning either deficient or elevated func-
tion. Our result argues that cancer cells show elevated HR, which
probably leads to deregulated recombination and the chromosomal
abnormalities frequently present in breast tumors.
What is the mechanism for increased HR in breast cancer cells? In
our study, HMECs proliferated with the same rate or faster than breast
cancer cells; thus, the high HR cannot be attributed to the higher
fraction of proliferating cells among the cancer cells. Multiple reports
detected increased levels of Rad51 protein or Rad51 paralogs in cancer
cells [14–23]. Rad51 is a mammalian homolog of bacterial RecA,
which plays a central role in HR (reviewed in Richardson [22]). Ele-
vated levels of Rad51 may be responsible for the increased HR. Indeed,
forced overexpression of Rad51 in rodent cells resulted in an increased
frequency of HR and chromosomal instability [26–28]. In addition to
the overexpression of Rad51, other proteins may stimulate HR. Over-
expression of DNA polymerase β, found in some breast, prostate, and
colon tumors, has been shown to stimulate HR in a Rad51-dependent
manner [29]. Elevated and deregulated HR may be highly deleterious
in many ways. The fidelity of HR may be compromised, or the check-
point controls of recombination may be altered leading to loss of
heterozygosity, translocations, and other rearrangements. These obser-
vations led to the hypothesis that elevated HR plays a role in carcino-
genesis [30,31]. However, HR frequency has not been systematically
examined in breast cancer. Our study provides the first analysis of
HR in a panel of human breast tumor cells, which gives experimental
support to the hypothesis that breast cancer cells have elevated HR.
A recent report showed that overexpression of Rad51 in BRCA1-
deficient DT40 cells rescued defects in proliferation, DNA damage
survival, and HR [32]. It was hypothesized that because BRCA1 facili-
tates Rad51 subnuclear assembly, in its absence, an excess of Rad51
may circumvent the requirement for BRCA1. Our study included only
sporadic breast cancer cell lines. Thus, up-regulation of HR is not lim-
ited to BRCA1-deficient tumors but frequently occurs in sporadic
tumors as well. The signaling pathways leading to the up-regulation
of HR may be different in BRCA1-deficient and sporadic tumors.
For example, fusion tyrosine kinases, which result from chromosomal
translocation and cause acute and chronic leukemias and non–Hodgkin
lymphoma, stimulate the expression of Rad51 and Rad51 paralogs
[18,33]. BCR/ABL was also shown to enhance Rad51 function by
phosphorylating Rad51 on Tyr-315 [18]. Understanding the pathways
leading to the up-regulation of HR in breast tumors may shed light on
the mechanisms of cancer development.
Figure 4. Survival curves of normal breast epithelial cells and breast
cancer cells after γ-irradiation. Cells were irradiated with increas-
ing doses of γ-irradiation. Survival was expressed as the relative
plating efficiencies of irradiated versus control cells. Each treatment
was repeated three to four times, and logistic regression using SAS
version 9.0 was used to fit a mortality curve for each cell line. The
HCC2218 cell line was not analyzed because these cells grow in sus-
pension culture.
Table 1. Sensitivity of Human Normal Mammary Epithelial Cells and Breast Cancer Cells to
γ-Irradiation (Gy).
Cell Line LD50 (95% CI) LD75 (95% CI)
HMEC1 2.10 (1.95-2.24) 3.34 (3.18-3.53)
HMEC2 2.58 (2.37-2.78) 3.78 (3.54-4.08)
HMEC3 1.79 (1.67-1.91) 2.69 (2.57-2.83)
HMEC4 2.13 (2.03-2.24) 2.95 (2.84-3.09)
HCC70 0.72 (0.30-0.95) 1.24 (1.02-1.44)
HCC1954 1.20 (0.90-1.42) 2.18 (1.98-2.42)
HCC202 2.02 (1.92-2.11) 2.66 (2.56-2.77)
MCF-7 1.43 (1.32-1.53) 2.09 (1.99-2.21)
T47-D 1.40 (1.27-1.51) 2.19 (2.08-2.31)
MDA-MB-231 0.41 (0.11-0.62) 1.15 (0.98-1.29)
MDA-MB-468 0.79 (0.45-1.03) 1.66 (1.46-1.85)
CI indicates confidence interval.
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Why do cancer cells upregulate HR? Does up-regulation of HR
predispose cells to malignant transformation or does it appear later as
an adaptation for the survival of malignant cells? Studies in BRCA1-
deficient cells suggest that up-regulation of HR is an adaptation, which
improves cell proliferation and resistance to DNA damage [32]. Ini-
tially, malignant transformation is associated with mutations such as
the activation of oncogenes and the inactivation of cell cycle checkpoint
apparatuses. Activated oncogenes lead to the firing of multiple replica-
tion origins. In the absence of cell cycle checkpoints, cells will continue
proliferation, leading to high level of replication-related lesions. We
speculate that, to counteract this replication, stress cancer cells may
upregulate HR repair. Of the two DSB repair pathways, HR pre-
dominantly repairs replication-related DSBs, whereas NHEJ is active
throughout the cell cycle. Therefore, this model provides an explana-
tion as to why HR but not NHEJ is increased in cancer cells. An alter-
native scenario, where a mutator phenotype caused by elevated HR
leads to malignant transformation, is also possible. In mammals, HR
is strictly controlled, and it plays a relatively minor role in DSB repair
when compared with NHEJ [34–36] because an inappropriate recom-
bination within the highly repetitive mammalian genomes may lead to
gross genomic rearrangements and cancer.
Gene expression profiling of melanoma samples found overexpres-
sion of genes involved in the repair of stalled replication forks in primary
tumors with a bad prognosis [37]. These studies led to a hypothesis that
the overexpression of DNA repair genes in primary tumors is associated
with a higher metastatic potential [38]. Our study does not allow for
differentiating between metastatic and primary tumors owing to the
small sample size; however, it complements the gene expression data
by demonstrating that the enzymatic activity of a DNA repair pathway
involved in the repair of replication forks is elevated in cancer cells.
Breast cancer cells showed no significant changes in NHEJ.Most cell
lines had the same frequency of NHEJ as the normal cells. However,
two cancer cell lines had extremely high NHEJ (Figure 2, B and C ).
Intact NHEJ in most breast cancer cell lines is consistent with a previ-
ous report where NHEJ was analyzed in vitro [39]. We did not find a
correlation between NHEJ and HR, which strengthens the idea that
only HR but not NHEJ is altered in breast cancer.
A recent study of NHEJ in urothelial carcinoma cells showed that
they performed NHEJ of compatible DNA ends more efficiently than
normal urothelial cells and that the carcinoma cells also displayed a
preferential use of microhomologies [40]. Our analysis of NHEJ-C
and NHEJ-I did not reveal any differences in the processing of
compatible and incompatible DNA ends between normal and malig-
nant breast epithelial cells. Thus, different cancers may have differ-
ential effect on the DSB repair pathways.
Breast cancer cells were more sensitive to γ-irradiation than normal
mammary epithelial cells, which perhaps reflects the susceptibility of
breast cancer to radiotherapy. Surprisingly, we did not find a correlation
betweenHR efficiency and resistance to γ-irradiation among the cancer
cells lines. Even the cell lines with the highest levels of HR were more
sensitive to radiation than the normal breast epithelial cells. Homolo-
gous recombination plays a relatively minor role in mammalian DSB
repair and its function is limited to the S/G2 phases [34,35]. Therefore,
increasedHRmay help cancer cells deal with endogenousDNAdamage
that arises during DNA replication but is not effective enough to protect
the cells from exogenous DNA damage applied to unsynchronized cells.
Themost important implication of our findings is that HR is a prom-
ising target for anticancer therapy. The inhibition ofNHEJ components
was shown to sensitize cancer cells to therapy [41–45]. However,
Figure 5. Relationship between survival after γ-irradiation (LD50)
and normal versus malignant cell status (A) and DSB repair effi-
ciency (B, C, D). (A) Normal cell are more resistant to γ-irradiation
(PMWU=0.014). (B,C)NeitherNHEJ-I norNHEJ-Cefficiency correlated
with radioresistance (NHEJ-I, rs = −0.082, P = .796; NHEJ-C, rs =
−0.009, P = .977). (D) HR efficiency negatively correlates with radio-
resistance (rs = −0.836, P = .008). However, this correlation dis-
appears if normal cells are excluded (see text).
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inhibition of NHEJ is toxic to normal cells and may not provide the
desired selectivity. Our results suggest that the inhibition of HR will
be selective against breast tumor cells. Inhibitors of HR proteins can
be used in combination with radiotherapy or chemotherapy to sensitize
the cells [46–48]. An even more attractive possibility would be to use
anti-HR agents alone, avoiding the toxicity of DNA-damaging agents.
If breast cancer cells require efficient HR for survival, inhibition of HR
may selectively kill the cancer cells in the absence of an exogenousDNA-
damaging agent. Such a strategy has been applied to selectively kill
BRCA2-deficient cells using poly-ADP-ribose-polymerase inhibitors
[49,50]. Our results hold promise that similar approaches can be devel-
oped to treat sporadic breast cancers. Another powerful approach would
be to use elevatedHR to transcriptionally target cancer cells.We recently
showed that the Rad51 promoter is on average 840-fold more active in
cancer cells than in normal cells and that the fusion of Rad51 promoter
with the diphtheria toxin gene selectively kills cancer cells [23]. Tran-
scriptionally targeted therapies taking advantage of upregulated HR
gene expression would allow effective elimination of cancerous cells
with no toxicity to normal tissue.
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Figure W1. Comparison of HR efficiency in different growth media.
Black bars represent HR efficiency in cells cultured in the recom-
mended medium (see Materials and Methods), also shown in Fig-
ure 2. White bars represent HR efficiency in cells cultured in the
MEGM recommended for HMEC (Clonetics). Homologous recombi-
nation efficiency was not significantly different between the two
growth conditions (HCC1954, P= .215; HCC70, P= .741) indicating
that MEGM does not have a suppressive effect on HR.
